Lafarge has first-hand experience of the ravages caused by HIV/Aids and malaria, particularly in the sub-Saharan countries where it operates. The Group quickly became involved in efforts to prevent and treat the illness with the support of specialized doctors and organizations such as the Care. Lafarge is also a member of the Global Business Coalition, which works to fight HIV/Aids and malaria.
As a result, in 2008, in sub-Saharan Africa where Lafarge employs around 8,000 people (almost 10% of its employees):
- 100% of employees have received regular information about H.I.V.,
- 75% have participated in voluntary, anonymous screening campaigns,
- 2,000 people (employees, dependants and community members) have benefited from free anti-retroviral treatment.
The anti-malaria program began in 2006. In 2007, Lafarge provided malaria treatment for 17,500 people (employees, dependants, sub-contractors and community members).
By 2010, these efforts against HIV and malaria will be extended to the other major developing countries where Lafarge operates.